Skip to main content
Account

Peer review reports

From: A prospective, open-label, randomized clinical trial to evaluate the efficacy and safety of remimazolam in patients undergoing EBUS-TBNA: REST trial design

Original Submission
11 Apr 2024 Submitted Original manuscript
9 May 2024 Author responded Author comments - June Hong Ahn
Resubmission - Version 2
9 May 2024 Submitted Manuscript version 2
10 May 2024 Author responded Author comments - June Hong Ahn
Resubmission - Version 3
10 May 2024 Submitted Manuscript version 3
Publishing
16 May 2024 Editorially accepted
17 May 2024 Article published 10.1186/s12890-024-03067-w

Learn about peer review

Back to article page

Navigation